Outcome of myeloma patients with COVID5 19 on active lenalidomide-based therapy: 6 Does lenalidomide protect from severe 7 COVID-19?
Tailor, Imran K.
Alshehry, Nawal F.
Zaidi, Syed Z.
Marei, Mohammed A.
Motabi, Ibrahim H.
Altaf, Syed Y.
MetadataShow full item record
Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedly have poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of ≥10% , , . A recent small study reported a high mortality rate among patients with myeloma and concurrent COVID-19 infection . Interestingly, one large study reported that active or recent chemotherapy was not a predictor of severe disease, whereas checkpoint inhibitor therapy and age over 65 years were associated with adverse outcomes . Here we describe the outcomes of three consecutive patients with myeloma and concurrent COVID-19 infection admitted at our tertiary care centre between April and June 2020, whilst on lenalidomide-based therapy, two of whom underwent autologous stem cell transplant, with at least 30 days of follow-up.
Link to resourcehttps://doi.org/10.1016/j.hemonc.2020.08.002
Estadísticas Google Analytics
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.